Healthcare provider profile · identity verified

Douglas Craig Smith, MD

Family Practice · RATON, NM · NPI 1598717217

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	354	87
Levothyroxine Sodium	Levothyroxine Sodium	342	75
Atorvastatin Calcium	Atorvastatin Calcium	315	87
Amlodipine Besylate	Amlodipine Besylate	243	54
Losartan Potassium	Losartan Potassium	213	48
Omeprazole	Omeprazole	200	51
Metoprolol Succinate	Metoprolol Succinate	184	45
Gabapentin	Gabapentin	152	30
Metformin Hcl	Metformin Hcl	134	35
Pantoprazole Sodium	Pantoprazole Sodium	127	35
Tamsulosin Hcl	Tamsulosin Hcl	123	30
Hydrochlorothiazide	Hydrochlorothiazide	121	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	119	22
Tramadol Hcl	Tramadol Hcl	107	29
Alprazolam	Alprazolam	106	14
Rosuvastatin Calcium	Rosuvastatin Calcium	91	24
Allopurinol	Allopurinol	76	16
Furosemide	Furosemide	69	23
Simvastatin	Simvastatin	69	18
Albuterol Sulfate Hfa	Albuterol Sulfate	68	25
Carvedilol	Carvedilol	67	19
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	62	suppressed
Sertraline Hcl	Sertraline Hcl	60	16
Metformin Hcl Er	Metformin Hcl	56	18
Potassium Chloride	Potassium Chloride	53	12
Montelukast Sodium	Montelukast Sodium	52	18
Eliquis	Apixaban	51	11
Fluoxetine Hcl	Fluoxetine Hcl	50	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	50	suppressed
Pravastatin Sodium	Pravastatin Sodium	48	11
Zolpidem Tartrate	Zolpidem Tartrate	48	suppressed
Trazodone Hcl	Trazodone Hcl	47	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	44	11
Alendronate Sodium	Alendronate Sodium	43	11
Famotidine	Famotidine	43	13
Clopidogrel	Clopidogrel Bisulfate	41	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	41	11
Ibuprofen	Ibuprofen	41	12
Meloxicam	Meloxicam	41	12
Finasteride	Finasteride	39	12
Buspirone Hcl	Buspirone Hcl	37	suppressed
Xarelto	Rivaroxaban	37	suppressed
Estradiol	Estradiol	36	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	36	suppressed
Lorazepam	Lorazepam	33	suppressed
Spironolactone	Spironolactone	33	suppressed
Synthroid	Levothyroxine Sodium	33	suppressed
Irbesartan	Irbesartan	32	suppressed
Citalopram Hbr	Citalopram Hydrobromide	31	suppressed
Glipizide	Glipizide	30	suppressed
Oxycodone Hcl	Oxycodone Hcl	30	suppressed
Baclofen	Baclofen	29	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	27	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	27	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Warfarin Sodium	Warfarin Sodium	27	suppressed
Atenolol	Atenolol	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	26	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Trulicity	Dulaglutide	26	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	24	suppressed
Azithromycin	Azithromycin	23	17
Ciprofloxacin Hcl	Ciprofloxacin Hcl	23	20
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Farxiga	Dapagliflozin Propanediol	23	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	22	suppressed
Jardiance	Empagliflozin	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Celecoxib	Celecoxib	21	suppressed
Fluticasone Propionate	Fluticasone Propionate	21	suppressed
Enalapril Maleate	Enalapril Maleate	20	suppressed
Glimepiride	Glimepiride	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Ozempic	Semaglutide	20	suppressed
Clonazepam	Clonazepam	19	suppressed
Temazepam	Temazepam	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Spiriva Respimat	Tiotropium Bromide	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	11
Chlorthalidone	Chlorthalidone	17	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	17	suppressed
Praluent Pen	Alirocumab	17	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Humalog Kwikpen U-100	Insulin Lispro	15	suppressed
Ibu	Ibuprofen	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Bumetanide	Bumetanide	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Armour Thyroid	Thyroid,pork	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Diazepam	Diazepam	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Methylprednisolone	Methylprednisolone	13	13
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Digoxin	Digoxin	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	11
Fludrocortisone Acetate	Fludrocortisone Acetate	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Tresiba Flextouch U-200	Insulin Degludec	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error